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Table
Parameter BL Change from BL at:
Wk2 Wk3 Wk4 Wk5 Wk7 Wk9 Wk11 Wk13 Mo4 Mo5 Mo6
BK viremia* (log10 c/mL) 6.2 -0.6 -1.4 -1.8 -2.1 -2.4 -2.7 -3.0 -3.0 -3.9 -3.9 -3.3
BK viruria* (log10 c/mL) 8.7 ND ND -0.7 -1.0 -1.1 -1.5 ND -1.9 -2.1 ND ND
Cr (mg/dL) 2.6 +0.5 +0.3 +0.6 +0.5 +1.0 +0.8 +1.1 +1.2 +0.9 +1.0 +1.3
BUN (mg/dL) 39 -2 -3 0 -2 0 -4 -4 -2 +2 -7 -9
GFR (mL/min/1.73m2) 27.1 -5.0 -3.2 -5.8 -5.0 -8.5 -7.2 -9.1 -9.6 -7.9 -8.5 -10.2
ND indicates not determined
* Viracor BKV qPCR assays in plasma (LLOD, 2 log10 c/mL) or urine (LLOD ¼ 2.7 log10 c/mL)
Figure 1.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312 S303GvHD (treated with alemtuzumab/mycophenolate mofetil
[MMF]). He has remained on sirolimus and MMF. At +16 mos
serum creatinine (Cr) was increasing, BKVN was diagnosed
by biopsy and he was enrolled in CMX001-350.
Methods: CMX001 was given orally at 100 mg twice-weekly
for 6 mos (max tx duration under CMX001-350). Pt was
assessed weekly (Wks 2-5), biweekly (Wks 7-13), and
monthly (Mos 4-6).
Results: Baseline (BL) and changes from BL in BK viremia/
viruria, Cr, BUN and estimated glomerular ﬁltration rate
(GFR, MDRD4) are shown below. No drug-related adverse
events (AEs) or serious AEs were reported. The pt continues
on CMX001 under separate EIND provisions and has stable
renal function and no HD.
Conclusions: BKVN may be underdiagnosed in HSCT. In 1 pt
treated with CMX001, the drug was well tolerated and
controlled the BK viremia. After 6 mos therapy, he has stable
renal functionwithout HD. Our data supports a potential role
for CMX001 in the tx of BKVN.
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Dose intensity is important for disease control in alloge-
neic stem cell transplant (AlloSCT). There is no prospective
data to determine the ideal dose for intravenous busulfan to
be used in reduced intensity AlloSCT. We conducted a phase
I/II controlled randomized study to determine the optimal
dosing schedule of intravenous busulfan. Patients with
advanced hematologic malignancies, 75 years with HLA-
compatible donor were eligible. In the phase 1 portion, seven
dose levels were explored. All patients received ﬂudarabine
at 30mg/m2/d for 4 days. Dose level 5 (11.2mg/kg) was
chosen to be tested for phase II cohort. Eighty patients with
a median age of 56 years were enrolled with 40% having
relapsed/refractory disease. Engraftment occurred in 91%
and complete response was documented in 79% patients
after undergoing transplant. At a median follow up of 91
months, no signiﬁcant difference was seen in terms of non-
relapse mortality of 34% for dose level 5 (11.2mg/kg) vs. 23%
for all other dose levels (P ¼ .4). Signiﬁcant improvement in
cumulative incidence of relapse of 43% vs. 68% (P ¼ .02);
relapse-free-survival of 25% vs. 9% (P ¼ .017) and overall-survival of 27% vs. 9% (P ¼ .037) (Figure 1) was demonstrated
with the dose intensiﬁcation of busulfan. We conclude that
optimizing intravenous busulfan dose intensity in the
preparative regimen leads to improvement in PFS and OS of
patients with advanced hematologic malignancies and may
overcome disease associated poor prognostic factors.388
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Background: Several methods are employed to predict the
outcome of patients undergoing allogeneic hematopoietic
cell transplantation (HCT), including patient characteristics
(e.g., age, performance status, concurrent comorbidities),
diagnosis, and disease status. Armand, et al. (Blood
2012;120:905-913) validated a disease risk index using
diagnosis, cytogenetics, and disease status, which predicted
for overall and progression-free survival. To test this disease
risk index in our patient population, we applied it to patients
receiving ﬂudarabine and pharmacokinetically dose-tar-
geted intravenous busulfan myeloablative conditioning fol-
lowed by allogeneic peripheral blood HCT.
Methods:We analyzed a cohort of 322 patients transplanted
between 2004 and 2009 and assigned them to disease (low,
intermediate, and high) and stage (low and high) risk groups
